To include your compound in the COVID-19 Resource Center, submit it here.

GPCR gambit

Anaphore buys RuiYi for GPCR-targeting mAb platform and foothold in China

Although Anaphore Inc. has yet to enter the clinic with a program from its protein therapeutics platform, the company jumped at the opportunity to add a second biologics technology and thinks last month's stock acquisition of RuiYi Inc. will allow it to accomplish the difficult task of targeting GPCRs with mAbs.

Anaphore's TrimerX technology is based on tetranectin, a protein that contains five loops on each of its three plasminogen binding domains. By altering the

Read the full 749 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE